Norton Rose Fulbright represents Alaunos Therapeutics in concurrent financings

Global law firm Norton Rose Fulbright represented Alaunos Therapeutics (NASDAQ: TCRT) (Alaunos) in a Registered Direct Offering and concurrent private placement of A-2 convertible preferred stock to a single institutional investor, which both closed on June 24, 2025.

The Registered Direct Offering closed with gross proceeds of US$2.05 million at a purchase price of US$3.36 per share, pursuant to the company’s shelf registration statement on Form S-3.

The preferred stock issuance closed at a purchase price of US$1,000 per share for an aggregate purchase price of US$850,000. This issuance follows a placement of series A-1 convertible preferred stock from April 2025.

Alaunos, a preclinical obesity health drug development company focused on developing a compound for oral obesity drug, plans to use the funding from both transactions for general corporate purposes.

Based in Houston, Alaunos aims to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products.

Norton Rose Fulbright’s deal team was led by Amelia Zhang (Houston) and Brandon Byrne (Dallas) and included Lee McIntyre, Danielle Bodunrin, Sloka Srisai Valleru Borrego (Houston) and Siyi Zhu (New York).